Selective phosphodiesterase inhibitors modulate the activity of alveolar macrophages from sensitized guinea-pigs.

@article{Germain1998SelectivePI,
  title={Selective phosphodiesterase inhibitors modulate the activity of alveolar macrophages from sensitized guinea-pigs.},
  author={No{\"e}lla Germain and Bernadette Bertin and A Legendre and Brigitte Martin and Vincent Lagente and Adrian N. Payne and Elisabeth Boichot},
  journal={The European respiratory journal},
  year={1998},
  volume={12 6},
  pages={
          1334-9
        }
}
The aim of this study was to investigate the effects of selective phosphodiesterase (PDE)3 and PDE4 inhibitors on arachidonate release by alveolar macrophages from sensitized and challenged guinea-pigs. Guinea-pigs were sensitized and challenged with ovalbumin administered by aerosol. Bronchoalveolar lavage was performed 48 h later and the PDE and cyclic adenosine monophosphate (cAMP) contents of or the arachidonate release from alveolar macrophages, stimulated in vitro with N-formyl-Met-Leu… Expand
Metabolism of cyclic GMP in peritoneal macrophages of rat and guinea pig.
TLDR
It is indicated that particulate GC-A is the main active form of GC in the rat PM, while in guinea pig macrophages the sGC activity dominates, which concludes that the mechanisms regulating cGMP metabolism in PM are species-specific. Expand
Expression and activity of cGMP-dependent phosphodiesterases is up-regulated by lipopolysaccharide (LPS) in rat peritoneal macrophages.
TLDR
Results show that in rat PMs expression of cGMP-dependent PDEs positively correlates with the activation state of cells, and the fact that most of these Pdes hydrolyze also cAMP indicates that cG MP can play a role of potent regulator of cAMP signaling in macrophages. Expand
Hydrolysis of cyclic GMP in rat peritoneal macrophages.
TLDR
The PDEs of families 2, 5, 10 and 11 are potential candidates for cGMP hydrolysis in the rPM and may not only regulate thecGMP level in a feedback-controlled way but also link cG MP-dependent pathways with those regulated by cAMP. Expand
Phosphodiesterase 4 (PDE4) inhibitors in asthma and chronic obstructive pulmonary disease (COPD).
  • M. Barnette
  • Medicine
  • Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques
  • 1999
TLDR
This chapter will review the evidence demonstrating the ability of PDE4 inhibitors to modify airway obstruction, airway inflammation and airway remodelling and hyperreactivity, and present some preliminary findings obtained with theses compounds in clinical trials. Expand
Relaxant effect of YM976, a novel phosphodiesterase 4 inhibitor, on bovine tracheal smooth muscle.
TLDR
It is suggested that YM976 relaxes tracheal smooth muscle, probably through the cAMP-dependent mechanism. Expand
Effects of interleukin‐10 and modulators of cyclic AMP formation on endotoxin‐induced inflammation in rat lung
TLDR
The present data show that the selective PDE4 inhibitor, rolipram, and the non‐selective PDE inhibitor, theophylline, markedly reduced the pulmonary inflammation associated with acute lung injury in the rat. Expand
The synthetic peptide octarphin activates soluble guanylate cyclase in macrophages
The effect of the peptide octarphin (TPLVTLFK), a selective agonist of the nonopioid β-endorphin receptor, on the activity of soluble (sGC) and membrane-bound guanylate cyclase (mGC) of peritonealExpand
Metalloelastase (MMP-12) induced inflammatory response in mice airways: effects of dexamethasone, rolipram and marimastat.
TLDR
The effects of treatment by anti-inflammatory compounds, dexamethasone and rolipram and a non-specific matrix metalloproteinase (MMP) inhibitor, marimastat indicate that MMP-12 instillation in mice could highlight some of the inflammatory response seen in COPD and could be used for the pharmacological evaluation of new anti- inflammatory mechanisms of action. Expand
Impaired neonatal macrophage phagocytosis is not explained by overproduction of prostaglandin E2
TLDR
It is suggested that elevated production of PGE2 and decreased production of LTB4 do not contribute to impaired opsonized macrophage phagocytosis and highlight an important difference between young and adult AMs. Expand
Cyclic nucleotide phosphodiesterases.
  • D. Essayan
  • Biology, Medicine
  • The Journal of allergy and clinical immunology
  • 2001
TLDR
The available in vitro, preclinical, and clinical data supporting the potential for selective PDE inhibitors as immunomodulatory agents are reviewed. Expand
...
1
2
...

References

SHOWING 1-10 OF 37 REFERENCES
The effect of selective phosphodiesterase 3 and 4 isoenzyme inhibitors and established anti‐asthma drugs on inflammatory cell activation
TLDR
Data clearly show that both established anti‐asthma medication as well as PDE inhibitors have the potential to inhibit inflammatory cell activation in vitro but that the anti‐secretory actions of β2 agonists, corticosteroids and PDE inhibitor are distinct. Expand
Effects of isozyme-selective phosphodiesterase inhibitors on eosinophil infiltration in the guinea-pig lung.
TLDR
It is suggested that inhibitors of type IV phosphodiesterase have anti-inflammatory effects in the airways and may be useful in the treatment of asthma. Expand
Antigen challenge modifies the cyclic AMP response of inflammatory mediators and beta-adrenergic drugs in alveolar macrophages.
TLDR
Using selective receptor ligands, it is shown that beta 2-adrenoceptors and H2-subtype histamine receptors are functionally coupled to macrophage adenylate cyclase activity and sensitization does not affect the configuration of the receptor on the outer membrane, but affects other parts of the transmembrane signal system leading to the intracellular production of cyclic AMP. Expand
Modulation of cytokine-induced eosinophil infiltration by phosphodiesterase inhibitors.
TLDR
It is suggested that PDE IV inhibitors have antiinflammatory effects in the airways and may be useful in the treatment of asthma. Expand
Involvement of cyclic AMP in the effects of phosphodiesterase IV inhibitors on arachidonate release from mononuclear cells.
TLDR
The results suggest that the potent inhibition of arachidonate release from mononuclear cells by selective phosphodiesterase IV inhibitors may be due to increases in discrete pools of intracellular cAMP. Expand
Inhaled substance P induces activation of alveolar macrophages and increases airway responses in the guinea-pig
TLDR
Results suggest that SP contributes to the bronchial hyper-responsiveness in asthma and this probably through activation of alveolar macrophages. Expand
Immunochemical characterization of the distinct monocyte cyclic AMP-phosphodiesterase from patients with atopic dermatitis.
TLDR
The increased degradation of cAMP by a unique form of PDE may cause defective regulation of intracellular functions of AD monocytes, leading to the characteristic hyperreactive immune and inflammatory events. Expand
Stimulation of beta adrenoceptors in a human monocyte cell line (U937) up-regulates cyclic AMP-specific phosphodiesterase activity.
TLDR
Results indicate that the major PDE isozyme in the soluble fraction of U937 cells is PDE IV and that the activity of this enzyme is increased markedly in cells after prolonged exposure to agents that increase cAMP content. Expand
Theophylline and selective phosphodiesterase inhibitors as anti-inflammatory drugs in the treatment of bronchial asthma.
TLDR
The evidence that theophylline and the newer more selective type IV PDE isoenzyme inhibitors can inhibit the activation of inflammatory cell types, such as T-lymphocytes, eosinophils, mast cells and macrophages, in vitro is reviewed. Expand
Monocyte localization of elevated cAMP phosphodiesterase activity in atopic dermatitis.
TLDR
In spite of the increased rate of cAMP degradation in atopic leukocytes, the resting cAMP levels do not differ from those of normal subjects, and it is demonstrated that this results from increased catabolism due to elevated cAMP-phosphodiesterase activity. Expand
...
1
2
3
4
...